Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term use in combination with ADT and docetaxel in the treatment of mHSPC patients.
Epistemonikos ID: 0e2b03b8968a5edea6110d970e9e6f80e8554d68
First added on: May 15, 2024